Vivos Therapeutics (NASDAQ:VVOS) Releases Earnings Results, Misses Expectations By $0.01 EPS

Vivos Therapeutics (NASDAQ:VVOS) posted its earnings results on Thursday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.01), Zacks reports. Vivos Therapeutics had a negative return on equity of 335.04% and a negative net margin of 86.19%. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $3.63 million. During the same period in the previous year, the firm posted ($1.63) earnings per share.

Vivos Therapeutics Stock Performance

Shares of NASDAQ VVOS opened at $3.06 on Friday. The business has a 50 day simple moving average of $2.80 and a 200 day simple moving average of $3.55. Vivos Therapeutics has a 52 week low of $1.91 and a 52 week high of $6.28. The stock has a market cap of $18.02 million, a price-to-earnings ratio of -0.54 and a beta of 7.31.

Wall Street Analysts Forecast Growth

VVOS has been the topic of a number of recent analyst reports. Alliance Global Partners restated a “buy” rating on shares of Vivos Therapeutics in a research note on Tuesday, April 1st. Ascendiant Capital Markets decreased their price target on Vivos Therapeutics from $6.60 to $6.20 and set a “buy” rating for the company in a research note on Tuesday, April 15th.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.